Powering the Next Wave of Cardiometabolic Care
In the May issue of ONdrug Delivery magazine, SHL Medical’s Lars Berger and Eric Linvill share their insights on SHL’s role in supporting the advancement of metabolic care with our innovative autoinjector technologies.
Metabolic diseases pose complex challenges in today’s healthcare landscape. The authors state that the intricate connection between obesity and a diverse set of metabolic risk factors requires comprehensive treatment strategies that consider the interconnected nature of these conditions. With the increasing number of cardiometabolic drugs in the pharmaceutical pipeline, the development of drug delivery systems must rise to meet the demand for customized solutions available at scale.
The article further discusses SHL’s continued contribution in metabolic care. With over three decades of industry experience and collaboration with leading pharma and biotech companies, SHL has supported the launch of six combination products for cardiometabolic diseases since 2015. The market introduction of SHL’s Needle Isolation Technology (NIT®) in 2017 marks a significant milestone in novel cardiometabolic peptide delivery. Continuing on this success, SHL’s Molly® modular platform autoinjectors have also supported autoinjector combination products for type 2 diabetes and obesity.
Amidst the global obesity epidemic, the growing demand for at-home metabolic care calls for innovative autoinjector solutions. The authors emphasize that SHL Medical – as the pioneering leader in the self-injection space – is well-positioned to lead the drive for a promising market introduction and continued success of treatments for patients with metabolic disorders.
